Ergebnisse einschränken

Dokumententyp

Artikel (11)

Institution

National (11)

Spezialsammlung

National Sammlungen (11)

Sprache

Englisch (11)

Autor

Borner, M. (11)
Bauer, J. (4)
Pagani, O. (4)
Sessa, C. (4)
Crivellari, D. (3)
Goldhirsch, A. (3)
Graffeo, R. (3)
Helbling, D. (3)
Hess, D. (3)
Hess, V. (3)
Koeberle, D. (3)
Martinelli, G. (3)
Roth, A. (3)
Saletti, P. (3)
Baertschi, D. (2)
Dietrich, D. (2)
Lombardi, D. (2)
Mingrone, W. (2)
Nolè, F. (2)
Rauch, D. (2)
Ruhstaller, T. (2)
Thürlimann, B. (2)
Widmer, L. (2)
Winterhalder, R. (2)
Zucchetti, M. (2)
von Moos, R. (2)
Anchisi, S. (1)
BalmerMajno, S. (1)
Begbie, S. (1)
Benhattar, J. (1)

Mehr Weniger

Fachgebiet

Medizin, Technik, Ingenieurwissenschaften, Informatik (11)

Schlagwort

Original articles (3)
advanced breast cancer (2)
capecitabine (2)
docetaxel (2)
epidoxorubicin (2)
metastatic colorectal cancer (2)
original articles (2)
G-CSF (1)
Key words: burned-out tumor (1)
Original article (1)
Taxotere (1)
bevacizumab (1)
breast cancer (1)
central nervous system involvement (1)
cetuximab (1)
chemoradiation (1)
chemoradiotherapy (1)
esophageal carcinoma (1)
esophagus (1)
germ cell tumor (1)
induction chemotherapy (1)
letters to the editor (1)
maintenance therapy (1)
oral chemotherapy (1)
oral platinum analogue (1)
oxaliplatin (1)
panitumumab (1)
phase I (1)
preoperative (1)
radiotherapy (1)

Mehr Weniger

Ergebnisse einschränken

Dokumententyp

Institution

Spezialsammlung

Sprache

Autor

Fachgebiet

Schlagwort

Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis

Scholz, M. ; Zehender, M. ; Thalmann, G. N. ; Borner, M. ; Thöni, H. ; Studer, U. E.

In: Annals of Oncology, 2002, vol. 13, no. 1, p. 121-124

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days

Sessa, C. ; Minoia, C. ; Ronchi, A. ; Zucchetti, M. ; Bauer, J. ; Borner, M. ; de Jong, J. ; Pagani, O. ; Renard, J. ; Weil, C. ; D'lncalci, M.

In: Annals of Oncology, 1998, vol. 9, no. 12, p. 1315-1322

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

Helbling, D. ; Bodoky, G. ; Gautschi, O. ; Sun, H. ; Bosman, F. ; Gloor, B. ; Burkhard, R. ; Winterhalder, R. ; Madlung, A. ; Rauch, D. ; Saletti, P. ; Widmer, L. ; Borner, M. ; Baertschi, D. ; Yan, P. ; Benhattar, J. ; Leibundgut, E. O. ; Bougel, S. ; Koeberle, D.

In: Annals of Oncology, 2013, vol. 24, no. 3, p. 718-725

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Koeberle, D. ; Betticher, D. C. ; von Moos, R. ; Dietrich, D. ; Brauchli, P. ; Baertschi, D. ; Matter, K. ; Winterhalder, R. ; Borner, M. ; Anchisi, S. ; Moosmann, P. ; Kollar, A. ; Saletti, P. ; Roth, A. ; Frueh, M. ; Kueng, M. ; Popescu, R. A. ; Schacher, S. ; Hess, V. ; Herrmann, R.

In: Annals of Oncology, 2015, vol. 26, no. 4, p. 709-714

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

Borner, M. ; Koeberle, D. ; Von Moos, R. ; Saletti, P. ; Rauch, D. ; Hess, V. ; Trojan, A. ; Helbling, D. ; Pestalozzi, B. ; Caspar, C. ; Ruhstaller, T. ; Roth, A. ; Kappeler, A. ; Dietrich, D. ; Lanz, D. ; Mingrone, W.

In: Annals of Oncology, 2008, vol. 19, no. 7, p. 1288-1292

Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)

Ruhstaller, T. ; Widmer, L. ; Schuller, J. C. ; Roth, A. ; Hess, V. ; Mingrone, W. ; von Moos, R. ; Borner, M. ; Pestalozzi, B. C. ; BalmerMajno, S. ; Köberle, D. ; Terraciano, L. ; Schnider, A. ; Bodis, S. ; Popescu, R.

In: Annals of Oncology, 2009, vol. 20, no. 9, p. 1522-1528

Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab

Helbling, D. ; Borner, M.

In: Annals of Oncology, 2007, vol. 18, no. 5, p. 963-964

Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study

Pagani, O. ; Sessa, C. ; Nolè, F. ; Crivellari, D. ; Lombardi, D. ; Thürlimann, B. ; Hess, D. ; Borner, M. ; Bauer, J. ; Martinelli, G. ; Graffeo, R. ; Zucchetti, M. ; D'Incalci, M. ; Goldhirsch, A.

In: Annals of Oncology, 2000, vol. 11, no. 8, p. 985-991

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer

Pagani, O. ; Sessa, C. ; Martinelli, G. ; Crivellari, D. ; Buonadonna, A. ; Thürlimann, B. ; Hess, D. ; Borner, M. ; Bauer, J. ; Zampino, G. ; Zimatore, M. ; Graffeo, R. ; Riva, A. ; Goldhirsch, A.

In: Annals of Oncology, 1999, vol. 10, no. 5, p. 539-545

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

Scheithauer, W. ; McKendrick, J. ; Begbie, S. ; Borner, M. ; Burns, W. I. ; Burris, H. A. ; Cassidy, J. ; Jodrell, D. ; Koralewski, P. ; Levine, E. L. ; Marschner, N. ; Maroun, J. ; Garcia-Alfonso, P. ; Tujakowski, J. ; Van Hazel, G. ; Wong, A. ; Zaluski, J. ; Twelves, C.

In: Annals of Oncology, 2003, vol. 14, no. 12, p. 1735-1743